Melflufen Combo Earns FDA Priority Review for Triple-refractory Myeloma
The U.S. Food and Drug Administration (FDA) has…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Trial Begins Dosing of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma
The first patient has been dosed in a Phase…
Cilta-cel, CAR T-cell Treatment, Named Breakthrough Therapy in China
Legend Biotech and Janssen’s investigational CAR…
First-in-class Blenrep Approved by European Commission for Myeloma
The European Commission (EC) has approved Blenrep (…
FDA Approves Darzalex Triple Combo for Advanced Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved …
Darzalex Faspro Combo Shows Benefits for Relapsed, Refractory Myeloma in Phase 3 Trial
Darzalex Faspro (daratumumab and hyaluronidase) significantly extended the…
